Akums gets DCGI nod for triple combination diabetes medication
Akums Drugs and Pharmaceuticals has received approval from the Drug Controller General of India (DCGI) for a triple combination diabetes medication. The drug combines Sitagliptin 100, Pioglitazone 15, and Metformin 1000/500 to provide better treatment without the need for multiple drugs. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 27, 2023 Category: Pharmaceuticals Source Type: news

ADA: Screen All With Type 2 Diabetes for Fatty Liver Disease ADA: Screen All With Type 2 Diabetes for Fatty Liver Disease
A new update to the American Diabetes Association ' s Standards of Care advises use of the fibrosis-4 (FIB-4) index for screening and use of GLP-1 agonists or pioglitazone for treatment.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 26, 2023 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Pioglitazone restores mitochondrial function but does not spare cortical tissue following mild brain contusion - Hubbard WB, Vekaria HJ, Kalimon OJ, Spry ML, Brown EP, Kilbaugh TJ, Sullivan PG.
Pioglitazone interacts through the mitochondrial protein mitoNEET to improve brain bioenergetics following traumatic brain injury. To provide broader evidence regarding the therapeutic effects of pioglitazone after traumatic brain injury, the current study... (Source: SafetyLit)
Source: SafetyLit - March 13, 2023 Category: International Medicine & Public Health Tags: Economics of Injury and Safety, PTSD, Injury Outcomes Source Type: news

Diabetes Drug Tied to Lower Dementia Risk Diabetes Drug Tied to Lower Dementia Risk
New research supports the potential cognitive benefit of pioglitazone, particularly in the setting of high ischemic burden, suggesting a possible personalized avenue to treatment.Medscape Medical News (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - February 16, 2023 Category: Internal Medicine Tags: Neurology & Neurosurgery News Source Type: news

Pioglitazone Use Linked to Reduced Dementia Risk in T2DM
THURSDAY, Feb. 16, 2023 -- For patients with diabetes mellitus (DM), pioglitazone use is associated with a reduced risk for dementia, especially in those with a history of ischemic heart disease or stroke, according to a study published online Feb.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 16, 2023 Category: Pharmaceuticals Source Type: news

Diabetes drug may lower risk of DEMENTIA by up to a third, study suggests
Scientists in South Korea said that type 2 diabetics on pioglitazone - sold under the brand name Actos - may have a lower risk of dementia compared to other patients not on the drug. (Source: the Mail online | Health)
Source: the Mail online | Health - February 15, 2023 Category: Consumer Health News Source Type: news

Pioglitazone (marketed as Actos, Actoplus Met, Duetact, and Oseni) Information
(Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 7, 2022 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Glucose - Regulating Drugs Aid COVID - 19 Outcomes in Patients With Diabetes
Findings include GLP - 1R agonists and pioglitazone use, with drop in hospital admissions (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 9, 2021 Category: Respiratory Medicine Tags: Endocrinology, Family Medicine, Infections, Internal Medicine, Critical Care, Nursing, Pharmacy, Pulmonology, Journal, Source Type: news

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Provides Update on Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Plus Prednisone Combination
RARITAN, N.J., April 19, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that regulatory submissions based on the Phase 3 ACIS study, which evaluated the combination of ERLEADA® (apalutamide) and ZYTIGA® (abiraterone acetate) plus prednisone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC), will not be pursued. As presented at the American Society of Clinical Oncology’s Genitourinary (ASCO GU) Cancers Symposium in February 2021, the ACIS study met its primary endpoint of radiographic progression-free survival (rPFS); however, combination...
Source: Johnson and Johnson - April 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Presents Results from Phase 3 ACIS Study in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with ERLEADA ® (apalutamide) and ZYTIGA® (abiraterone acetate) Combination
RARITAN, N.J., February 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today results from the randomized, double-blind, placebo-controlled Phase 3 ACIS study, which met the primary endpoint of radiographic progression-free survival (rPFS) with a 31 percent reduction in the risk of radiographic progression or death in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) receiving androgen deprivation therapy (ADT). Patients in the trial received either a combination of ERLEADA® and ZYTIGA® plus prednisone (combination arm) or placebo and ZYTIGA® pl...
Source: Johnson and Johnson - February 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said Craig Tendler, M...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Newer Antidiabetic Drugs Linked to Improved Liver Enzymes, Steatosis Newer Antidiabetic Drugs Linked to Improved Liver Enzymes, Steatosis
Early evidence suggests that newer diabetes drugs such as pioglitazone may improve liver enzymes and hepatic steatosis and could possibly be useful in treating non-alcoholic fatty liver disease (NAFLD), researchers say.Reuters Health Information (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 6, 2020 Category: Endocrinology Tags: Gastroenterology News Source Type: news

FDA testing metformin for traces of nitrosamines
MHRA aware of issue and advises patients to continue to taking their diabetes medicine Related items fromOnMedica People on statins at greater risk of skin infections and diabetes Raised risk of MI and mortality when starting sulfonylurea Use of DPP-4 inhibitors associated with increased risk of IBD Vitamin D does not reduce kidney damage in type 2 diabetes Use pioglitazone only in selected patients, says EMA guidance (Source: OnMedica Latest News)
Source: OnMedica Latest News - December 9, 2019 Category: UK Health Source Type: news

Diabetes drug can relieve smoking withdrawal symptoms, study says
An Italian experiment on rats and mice found pioglitazone - sold under the brand name Actos - weakened the effects of nicotine withdrawal. (Source: the Mail online | Health)
Source: the Mail online | Health - November 4, 2019 Category: Consumer Health News Source Type: news